Best of ASCO - 2014 Annual Meeting



Attend this session at the
2019 ASCO Annual Meeting!

Session: Gastrointestinal (Colorectal) Cancer

Type: Oral Abstract Session

Time: Saturday June 1, 3:00 PM to 6:00 PM

Location: Hall B1

Three versus six months adjuvant FOLFOX or CAPOX for high risk stage II and stage III colon cancer patients: The efficacy results of Hellenic Oncology Research Group (HORG) participation to the International Duration Evaluation of Adjuvant chemotherapy (IDEA) project.


Gastrointestinal (Colorectal) Cancer

2019 ASCO Annual Meeting

Abstract No:

J Clin Oncol 37, 2019 (suppl; abstr 3500)

Author(s): Ioannis Sougklakos, Ioannis Boukovinas, Spyros Xynogalos, Stylianos Kakolyris, Nikolaos Ziras, Michael Vaslamatzis, Athanasios Athanasiadis, Alexandros Ardavanis, Nikolaos E. M. Androulakis, Athina Christopoulou, Paris Makrantonakis, Iliada Bompolaki, Charalampos Christofyllakis, Nikolaos K. Kentepozidis, Christos E. Emmanouilides, Charalambos Kouroussis, Efthimios Prinarakis, Ageliki Kalisperi, Dimitrios Mavroudis, Vassilis Georgoulias; University of Heraklion, Heraklion, Greece; Bioclinic Thessaloniki Medical Oncology Unit, Athens, Greece; Hellenic Oncology Research Group (HORG), Athens, Greece; University Hospital of Alexandroupolis, Athens, Greece; Metaxa Cancer Hosp, Athens, Greece; Department of Oncology Evaggelismos General Hospital, Athens, Greece; Larissa General Hospital, Larissa, Greece; Cancer Immunology and Immunotherapy Center, Saint Savas Cancer Hospital, Athens, Greece; Venizeleio General Hospital, Heraklion, Greece; Saint Andrew General Hospital, Patras, Greece; Theagenion Anticancer Hospital, Athens, Greece; Oncology Dept, Hania General Hospital, Hania, Greece; Hellenic Airforce General Hospital, Athens, Greece; Interbalkan Medical Center, Athens, Greece; University Hospital of Heraklion, Athens, Greece; Hellenic Oncology Research Group, Athens, Greece; Department of Medical Oncology, University General Hospital of Heraklion, Heraklion, Greece

Abstract Disclosures


Background: The IDEA aimed to investigate whether a 3-month (3M) of oxaliplatin/fluoropyrimidines-based adjuvant chemotherapy (CT) is non-inferior to the 6-month (6M) in 3-year disease free survival (DFS) in stage high risk stage II and in stage III colon cancer (CC). Methods: HORG-IDEA randomized patients between 3M and 6M of CT with FOLFOX4 or CAPOX with primary end point the 3 years DFS (3yDFS). Results: In total 1121 patients, 413 with high risk stage and 708 with stage IIICC, were randomized between May 2009 and October 2015. The median follow-up was 67 (38-126) months. There were 79 DFS events (43 in 3M and 38 in 6M arm) in high risk stage II patients leading to 3yDFS rate of 82.7 and 83.4% for 3M and 6M, respectively (HR: 1.05; 95%CI: 0.68-1.63, p = 0.829). Similarly, 214 DFS events (161 in 3M and 153 in 6M arm) has been recorded in stage III patients, leading to a 3yDFS rate of 72.9% in the 3M vs. 74.1% in the 6M (HR = 1.06; 95%CI: 0.81–1.42, p = 0.622). For high risk stage II patients receiving FOLFOX4, 3yDFS rate was 76.7% in the 3M vs.79.3% in the 6M (HR = 1.21; 95%CI: 0.54–2.70 p = 0.641). For high risk stage II patients receiving CAPOX 3-year DFS rate was 85.4% in the 3M vs. 83.8% in the 6M (HR = 0.99; 95%CI: 0.59–1.67 p = 0.968). For stage III CC patients receiving mFOLFOX6, 3-year DFS rate was 71.5% in the 3M vs.77.3% in the 6M (HR = 1.18; 95%CI: 0.74–1.86 p = 0.479). For stage III CC patients receiving CAPOX 3-year DFS rate was 74.5% in the 3M vs. 74.7% in the 6M (HR = 0.99; 95%CI: 0.70–1.44 p = 0.991). Conclusions: The results of the HORG-IDEA study are in line with those of the global IDEA project, indicating that 3yDFS is depended on the administered adjuvant regimen, and the choice of regimen and duration should be personalized. Clinical trial information: NCT01308086

Other Abstracts in this Sub-Category:


1. Prospective pooled analysis of four randomized trials investigating duration of adjuvant (adj) oxaliplatin-based therapy (3 vs 6 months {m}) for patients (pts) with high-risk stage II colorectal cancer (CC).

Meeting: 2019 ASCO Annual Meeting Abstract No: 3501 First Author: Timothy Iveson
Category: Gastrointestinal (Colorectal) Cancer - Local-Regional


2. Re-evaluating disease-free survival (DFS) as an endpoint versus overall survival (OS) in adjuvant colon cancer (CC) trials with chemotherapy +/- biologics: An updated surrogacy analysis based on 18,886 patients (pts) from the Accent database.

Meeting: 2019 ASCO Annual Meeting Abstract No: 3502 First Author: Qian Shi
Category: Gastrointestinal (Colorectal) Cancer - Local-Regional


3. FOxTROT: an international randomised controlled trial in 1052 patients (pts) evaluating neoadjuvant chemotherapy (NAC) for colon cancer.

Meeting: 2019 ASCO Annual Meeting Abstract No: 3504 First Author: Matthew T. Seymour
Category: Gastrointestinal (Colorectal) Cancer - Local-Regional